

Haitao Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315796/publications.pdf>

Version: 2024-02-01

44
papers

582
citations

759233

12
h-index

677142

22
g-index

46
all docs

46
docs citations

46
times ranked

749
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Sample size determination for mediation analysis of longitudinal data. BMC Medical Research Methodology, 2018, 18, 32. | 3.1 | 82 |
| 2 | The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number. Developmental Cell, 2018, 47, 576-591.e8. | 7.0 | 80 |
| 3 | Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine, 2018, 37, 2208-2222. | 1.6 | 57 |
| 4 | Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. Journal of Clinical Oncology, 2022, 40, 335-344. | 1.6 | 46 |
| 5 | A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 979-996. | 1.0 | 40 |
| 6 | Epigenetic Age Acceleration and Chronic Health Conditions Among Adult Survivors of Childhood Cancer. Journal of the National Cancer Institute, 2021, 113, 597-605. | 6.3 | 37 |
| 7 | Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine, 2015, 34, 1681-1694. | 1.6 | 23 |
| 8 | Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials, 2020, 92, 105972. | 1.8 | 18 |
| 9 | A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer, 2021, 127, 3825-3831. | 4.1 | 18 |
| 10 | Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. Oncotarget, 2017, 8, 6763-6774. | 1.8 | 18 |
| 11 | Persistent variations of blood DNA methylation associated with treatment exposures and risk for cardiometabolic outcomes in long-term survivors of childhood cancer in the St. Jude Lifetime Cohort. Genome Medicine, 2021, 13, 53. | 8.2 | 16 |
| 12 | A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials, 2014, 11, 49-59. | 1.6 | 14 |
| 13 | A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2021, 27, 2442-2451. | 7.0 | 13 |
| 14 | Adaptive dose modification for phase I clinical trials. Statistics in Medicine, 2016, 35, 3497-3508. | 1.6 | 12 |
| 15 | A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine, 2017, 36, 266-279. | 1.6 | 11 |
| 16 | Feasibility and Acceptability of Light Therapy to Reduce Fatigue in Adolescents and Young Adults Receiving Cancer-Directed Therapy. Behavioral Sleep Medicine, 2021, 19, 492-504. | 2.1 | 11 |
| 17 | Radiotherapy alone for pediatric patients with craniopharyngioma. Journal of Neuro-Oncology, 2022, 156, 195-204. | 2.9 | 11 |
| 18 | Spinal changes after craniospinal irradiation in pediatric patients. Pediatric Blood and Cancer, 2020, 67, e28728. | 1.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28617. | 1.5 | 7 |
| 20 | Expanded study on the risk of lymphovascular space invasion and lymph node metastasis of endocervical adenocarcinoma using Pattern Classification: a single-centre analysis of 213 cases. <i>Pathology</i> , 2019, 51, 570-578. | 0.6 | 6 |
| 21 | A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. <i>Statistics in Medicine</i> , 2021, 40, 382-402. | 1.6 | 6 |
| 22 | Beginning Restorative Activities Very Early: Implementation of an Early Mobility Initiative in a Pediatric Onco-Critical Care Unit. <i>Frontiers in Oncology</i> , 2021, 11, 645716. | 2.8 | 6 |
| 23 | OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10521-10521. | 1.6 | 6 |
| 24 | The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. <i>PLoS ONE</i> , 2014, 9, e98147. | 2.5 | 5 |
| 25 | Blood DNA methylation signatures are associated with social determinants of health among survivors of childhood cancer. <i>Epigenetics</i> , 2022, , 1-15. | 2.7 | 5 |
| 26 | A Novel Bayesian Seamless Phase I/II Design. <i>PLoS ONE</i> , 2013, 8, e73060. | 2.5 | 4 |
| 27 | Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age. <i>Journal of Clinical Oncology</i> , 2021, 39, 2676-2684. | 1.6 | 4 |
| 28 | Light Therapy for QoL/Depression in AYA With Cancer: A Randomized Trial. <i>Journal of Pediatric Psychology</i> , 2022, 47, 306-317. | 2.1 | 4 |
| 29 | An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. <i>PLoS ONE</i> , 2018, 13, e0208354. | 2.5 | 3 |
| 30 | Bayesian single-arm phase II trial designs with time-to-event endpoints. <i>Pharmaceutical Statistics</i> , 2021, 20, 1235-1248. | 1.3 | 3 |
| 31 | A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2014, 43, 254-268. | 1.2 | 1 |
| 32 | A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. <i>PLoS ONE</i> , 2020, 15, e0237254. | 2.5 | 1 |
| 33 | Treatment-related calvarial lesions in pediatric brain tumor survivors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28189. | 1.5 | 1 |
| 34 | Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. <i>Pharmaceutical Statistics</i> , 2020, 19, 561-582. | 1.3 | 1 |
| 35 | A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. <i>Contemporary Clinical Trials</i> , 2021, 108, 106504. | 1.8 | 1 |
| 36 | Effects of lymph node metastasis of thoracic esophageal squamous cell carcinoma on design of radiotherapy target volume. <i>Pakistan Journal of Medical Sciences</i> , 2018, 35, 177-182. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. BMC Medical Research Methodology, 2021, 21, 278. | 3.1 | 1 |
| 38 | A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharmaceutical Statistics, 2022, 21, 1149-1166. | 1.3 | 1 |
| 39 | Abstract 685: A social epigenomic investigation of racial disparity in pulmonary impairment among aging survivors of childhood cancer. , 2021, , . | | 0 |
| 40 | Title is missing!. , 2020, 15, e0237254. | | 0 |
| 41 | Title is missing!. , 2020, 15, e0237254. | | 0 |
| 42 | Title is missing!. , 2020, 15, e0237254. | | 0 |
| 43 | Title is missing!. , 2020, 15, e0237254. | | 0 |
| 44 | 0500 Increased adherence to light therapy and psychosocial outcomes in adolescents and young adults with cancer. Sleep, 2022, 45, A221-A221. | 1.1 | 0 |